Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4580-4596

  Stößel, Anne ^a   Schlenk, Miriam ^a   Hinz, Sonja ^a   Küppers, Petra ^a   Heer, Jag ^b   Gütschow, Michael ^a   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLOROPHENOXY) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL) ACETAMIDE; 2 (3 CHLOROPHENOXY) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)ACETAMIDE; 3 (2 BROMOPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)PROPANAMIDE; 3 (2 FLUOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)PROPANAMIDE; 3 (3 CHLOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)ACRYLAMIDE; 3 (3 METHOXYPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)ACRYLAMIDE; 3 (3 METHOXYPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)PROPANAMIDE; 3 (3 METHOXYPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)PROPIOLAMIDE; 3 (3,4 DICHLOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)PROPANAMIDE; 4 (3 CHLOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BUT 3 ENAMIDE; 4 (3 CHLOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BUTANAMIDE; 4 (3 METHOXYPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BUT 3 ENAMIDE; 4 (3 METHOXYPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BUTANAMIDE; 4 (3,4 DICHLOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BUT 3 ENAMIDE; 4 (3,4 DICHLOROPHENYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BUTANAMIDE; 4 (4 (2 CHLOROBENZYL)PIPERAZINE 1 CARBONYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BENZAMIDE; 4 (4 (3 CHLOROBENZYL)PIPERAZINE 1 CARBONYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BENZAMIDE; 4 (4 (4 CHLOROBENZYL)PIPERAZINE 1 CARBONYL) N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL)BENZAMIDE; 4H 3,1 BENZOTHIAZIN 4 ONES; ADENOSINE A2A RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENZOTHIAZINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL) 4 PHENYLBUT 3 ENAMIDE; N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL) 4 PHENYLBUTANAMIDE; N (6 CHLORO 4 OXO 4H 3,1 BENZOTHIAZIN 2 YL) 4 PHENYLBUTANAMIDE; N (6 METHYL 4 OXO 4H 3,1 BENZOTHIAZIN 2 YL) 4 PHENYLBUTANAMIDE; N METHYL N (4 OXO 4H 3,1 BENZOTHIAZIN 2 YL) 4 PHENYLBUTANAMIDE; RADIOLIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FEMALE; HUMAN; HYDROGEN BOND; HYDROGENATION; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN BINDING; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 84879045217     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400336x     Document Type: Article

References (76)

1. Samii, A.; Nutt, J. G.; Ransom, B. R. Parkinson's disease Lancet 2004, 363, 1783-1793 (Pubitemid 38698383)
2. 2A receptors in Parkinson's disease Trends Neurosci. 2006, 29, 647-654 (Pubitemid 44602262)
3. Allain, H.; Bentué-Ferre, D.; Akwa, Y. Disease-modifying drugs and Parkinson's disease Prog. Neurobiol. 2008, 84, 25-39 (Pubitemid 350258711)
4. Rezak, M. Current pharmacotherapeutic treatment options in Parkinson's disease Dis. Mon. 2007, 53, 214-222 (Pubitemid 46935688)
5. Lees, A. Alternatives to levodopa in the initial treatment of early Parkinson's disease Drugs Aging 2005, 22, 731-740 (Pubitemid 41242117)
6. Dunkel, P.; Chai, C. L.; Sperlágh, B.; Huleatt, P. B.; Mátyus, P. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis Expert Opin. Invest. Drugs 2012, 21, 1267-1308
7. 2A adenosine receptor antagonists in the therapy of Parkinson's disease Pharmacol. Ther. 2011, 132, 280-299
8. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Linden, J.; Müller, C. E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update Pharmacol. Rev. 2011, 63, 1-34
9. 2A receptors Prog. Neurobiol. 1999, 59, 355-396 (Pubitemid 29352341)
10. 2 receptor interactions. Implications for the function of G-protein coupled receptors Curr. Pharm. Des. 2009, 14, 1468-1474 (Pubitemid 351997812)
11. Ferré, S.; Fredholm, B. B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia Trends Neurosci. 1997, 20, 482-487 (Pubitemid 27421712)
12. Ferré, S.; Navarro, G.; Casadó, V.; Cortés, A.; Mallol, J.; Canela, E. I.; Lluís, C.; Franco, R. G protein-coupled receptor heteromers as new targets for drug development Prog. Mol. Biol. Transl. Sci. 2010, 91, 41-52
13. 2 dopamine dependent activation of Fos in the striatopallidal pathway Neuroscience 1995, 68, 721-728
14. Lozano, A. M.; Lang, A. E.; Hutchison, W. D.; Dostrovsky, J. O. New developments in understanding the etiology of Parkinson's disease and in its treatment Curr. Opin. Neurobiol. 1998, 8, 783-790 (Pubitemid 28564477)
15. 2A receptors: a new strategy for basal ganglia disorders Recent Pat. CNS Drug Discovery 2007, 2, 1-21 (Pubitemid 46729088)
16. 2A Adenosine receptor antagonists-future drugs for Parkinson's disease? Drugs Future 2000, 25, 1043-1052
17. Müller, C. E.; Jacobson, K. A. Recent developments in adenosine receptor ligands and their potential as novel drugs Biochim. Biophys. Acta, Biomembr, 2011, 1290-1308
18. 3 adenosine receptor antagonists Eur. J. Med. Chem. 2003, 38, 367-382 (Pubitemid 36581870)
19. Baraldi, P. G.; Tabrizi, M. A.; Gessi, S.; Borea, P. A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility Chem. Rev. 2008, 108, 238-263 (Pubitemid 351176408)
20. 2A receptor antagonist for the potential treatment of parkinsonism and other disorders IDrugs 2010, 13, 723-731
21. 2A receptor ligands Handb. Exp. Pharmacol. 2009, 193, 59-98
22. 2A antagonist SYN115 in Parkinson disease J. Neurosci. 2010, 30, 16284-16292
23. Gütschow, M.; Schlenk, M.; Gäb, J.; Paskaleva, M.; Alnouri, M. W.; Scolari, S. W.; Iqbal, J.; Müller, C. E. Benzothiazinones: A novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives J. Med. Chem. 2012, 55, 3331-3341
24. 2A adenosine receptor ligands J. Med. Chem. 2010, 53, 3748-3755
25. 2A receptor ligands ChemMedChem 2011, 6, 2302-2311
26. Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2 H -chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor J. Med. Chem. 2009, 52, 6685-6706
27. Maccioni, E.; Alcaro, S.; Cirilli, R.; Vigo, S.; Cardia, M. C.; Sanna, M. L.; Meleddu, R.; Yanez, M.; Costa, G.; Casu, L.; Matyus, P.; Distinto, S. 3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B J. Med. Chem. 2011, 54, 6394-6398
28. Gaspar, A.; Silva, T.; Yáñez, M.; Vina, D.; Orallo, F.; Ortuso, F.; Uriarte, E.; Alcaro, S.; Borges, F. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors J. Med. Chem. 2011, 54, 5165-5173
29. Riederer, P.; Lachenmayer, L.; Laux, G. Clinical applications of MAO-inhibitors Curr. Med. Chem. 2004, 11, 2033-2043 (Pubitemid 38967728)
30. Youdim, M. B.; Bakhle, Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness Br. J. Pharmacol. 2006, 147, S287-S296
31. Nicotra, A.; Pierucci, F.; Parvez, H.; Senatori, O. Monoamine oxidase expression during development and aging NeuroToxicology 2004, 25, 155-165 (Pubitemid 38044177)
32. Sayre, L. M.; Perry, G.; Smith, M. A. Oxidative stress and neurotoxicity Chem. Res. Toxicol. 2008, 21, 172-188 (Pubitemid 351219718)
33. PaÌŠlhagen, S.; Heinonen, E.; Hägglund, J. Selegiline slows the progression of the symptoms of Parkinson disease Neurology 2006, 66, 1200-1206
34. Parkinson study group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease Arch. Neurol. 2004, 61, 561-566
35. Schapira, A. H. V. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects CNS Drugs 2011, 25, 1061-1071
36. Schapira, A. H.; Stocchi, F.; Borgohain, R.; Onofrj, M.; Bhatt, M.; Lorenzana, P.; Lucini, V.; Giuliani, R.; Anand, R. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease Eur. J. Neurol. 2013, 20, 271-280
37. Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases Curr. Med. Chem. 2011, 18, 4568-4587
38. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543 (Pubitemid 41504710)
39. Patyar, S.; Prakash, A.; Medhi, B. Dual inhibition: a novel promising pharmacological approach for different disease conditions J. Pharm. Pharmacol. 2011, 63, 459-471
40. Elsinghorst, P. W.; Härtig, W.; Gündisch, D.; Mohr, K.; Tränkle, C.; Gütschow, M. A hydrazide linker strategy for heterobivalent compounds as ortho- and allosteric ligands of acetylcholine-binding proteins Curr. Top. Med. Chem. 2011, 11, 2731-2748
41. Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlágh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Mátyus, P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target Curr. Med. Chem. 2008, 15, 1827-1839
42. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment Curr. Drug Targets 2012, 13, 483-494
43. Youdim, M. B.; Fridkin, M.; Zheng, H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases Mech. Ageing Dev. 2005, 126, 317-326 (Pubitemid 40038353)
44. Samadi, A.; de los Ríos, C.; Bolea, I.; Chioua, M.; Iriepa, I.; Moraleda, I.; Bartolini, M.; Andrisano, V.; Gálvez, E.; Valderas, C.; Unzeta, M.; Marco-Contelles, J.; Multipotent, M. A. O. and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine Eur. J. Med. Chem. 2012, 52, 251-262
45. Bolea, I.; Juárez-Jiménez, J.; de Los Ríos, C.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N -[(5-(benzyloxy)-1-methyl-1 H -indol-2-yl)methyl]- N -methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease J. Med. Chem. 2011, 54, 8251-8270
46. 2A receptor antagonism J. Biol. Chem. 2002, 277, 36040-36044
47. Aguiar, L. M.; Maceîdo, D. S.; Vasconcelos, S. M.; Oliveira, A. A.; de Sousa, F. C.; Viana, G. S. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats Brain Res. 2008, 1191, 192-199
48. 2A receptors for Parkinson's disease Neurotherapeutics 2009, 6 (1) 41-151
49. 2A receptor antagonists Bioorg. Med. Chem. 2003, 11, 1299-1310 (Pubitemid 36293525)
50. 2A receptor by (E, E)-8-(4-phenylbutadien-1-yl)caffeine analogues Bioorg. Med. Chem. 2008, 16, 8676-8684
51. 2A antagonists/MAO-B inhibitors J. Med. Chem. 2013, 56, 1247-1261
52. 3-adenosine receptor antagonists J. Med. Chem. 2002, 45, 3440-3450 (Pubitemid 34824031)
53. 2A receptor antagonist MSX-2 Molecules 2008, 13, 348-359
54. 2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease J. Org. Chem. 2004, 69, 3308-3318 (Pubitemid 38621277)
55. 2A-adenosine receptor antagonists Eur. J. Med. Chem. 1997, 32, 709-719 (Pubitemid 27380209)
56. 2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7- methylxanthine J. Med. Chem. 1993, 36, 3731-3733 (Pubitemid 24004373)
57. Leistner, S.; Gütschow, M.; Stach, J. 2-Amino-3,1-benzothiazin-4- ones: synthesis, Dimroth rearrangement to quinazolin-4(3 H)-on-2(1 H)-thiones, and MS/MS-fragmentation Arch. Pharm. (Weinheim, Ger.) 1990, 323, 857-861
58. 2A receptor antagonists, PCT Int. Appl., 2008077557, 03 Jul 2008.
59. Travis, B. R.; Sivakumar, M.; Hollist, G. O.; Borhan, B. Facile oxidation of aldehydes to acids and esters with oxone Org. Lett. 2003, 5, 1031-1034 (Pubitemid 37141028)
60. Neumann, U.; Gütschow, M. 3,1-Benzothiazin-4-ones and 3,1-benzoxazin-4-ones: highly different activities in chymotrypsin inactivation Bioorg. Chem. 1995, 23, 72-88
61. 1 receptor antagonists Bioorg. Med. Chem. 2010, 18, 2195-2203
62. Müller, C. E.; Jacobson, K. A. Xanthines as Adenosine Receptor antagonists. In Methylxanthines. Handbook of Experimental Pharmacology 200, 1 st ed.; Fredholm, B. B., Ed.; Springer-Verlag: Berlin, Germany, 2011; pp 151-199.
63. 2A receptor antagonists for the treatment of Parkinson's disease Neurology 2003, 61, 101-106
64. 2-selective adenosine antagonists J. Med. Chem. 1993, 36, 1333-1342 (Pubitemid 23164489)
65. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Finberg, J.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M. B.; Weinstock, M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease J. Med. Chem. 2002, 45, 5260-5279 (Pubitemid 35429165)
66. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Sanna, M. L.; Gallinella, B.; Cirilli, R. Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-Arylthiazol-2-yl)-2-(3- methylcyclohexylidene)hydrazines J. Med. Chem. 2010, 53, 6516-6520
67. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P. A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors J. Med. Chem. 2006, 49, 6264-6272 (Pubitemid 44595203)
68. 2A adenosine receptors Eur. J. Pharm. Sci. 2000, 10, 259-265 (Pubitemid 30317461)
69. 2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity J. Med. Chem. 2009, 52, 3994-4006
70. 3 adenosine receptors Bioorg. Med. Chem. Lett. 2002, 12, 501-503 (Pubitemid 34113933)
71. Bulicz, J.; Bertarelli, D. C.; Baumert, D.; Fülle, F.; Müller, C. E.; Heber, D. Synthesis and pharmacology of pyrido[2,3- d ]-pyrimidinediones bearing polar substituents as adenosine receptor antagonists Bioorg. Med. Chem. 2006, 14, 2837-2849 (Pubitemid 43343671)
72. 1 adenosine receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 1989, 340, 679-683 (Pubitemid 20023156)
73. 2B receptor antagonists J. Med. Chem. 2006, 49, 4384-4391 (Pubitemid 44036682)
74. 1 adenosine receptors J. Nat. Prod. 2002, 65, 1479-1485 (Pubitemid 35239637)
75. 2B receptor: role in ligand binding and receptor function Biochem. Pharmacol. 2011, 82, 389-399
76. Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid Anal. Biochem. 1990, 189, 231-234